4-((3aS,4R,9bR)-3a,4,5,9b-tetrahydro-8-isopropyl-3H-cyclopenta[c]quinolin-4-yl)benzoic acid | 850824-08-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-((3aS,4R,9bR)-3a,4,5,9b-tetrahydro-8-isopropyl-3H-cyclopenta[c]quinolin-4-yl)benzoic acid
• 英文别名: 4-[(3aS,4R,9bR)-8-propan-2-yl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-4-yl]benzoic acid
• CAS: 850824-08-7
• 化学式: C₂₂H₂₃NO₂
• 分子量: 333.43
• InChiKey: RWGOYNCGDIHCFK-LQWHRVPQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS<br/>[FR] COMPOSÉS TRICYCLIQUES SUBSTITUÉS POSSÉDANT UNE ACTIVITÉ CONTRE LES RÉCEPTEURS EP1
  申请人：ALMIRALL SA

  公开号：WO2013149997A1

  公开（公告）日：2013-10-10

  The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

  本发明属于EP1受体配体领域。更具体地，它涉及具有对EP1受体具有很高亲和力和选择性的一般式(I)化合物。该发明还涉及它们的制备方法，以及它们作为药物用于治疗和/或预防由EP1受体介导的疾病或紊乱，以及包含它们的药物组合物。
• Substituted tricyclic compounds with activity towards ep1 receptors
  申请人：Almirall, S.A.

  公开号：EP2647628A1

  公开（公告）日：2013-10-09

  The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

  本发明属于 EP1 受体配体领域。更具体地说，它指的是对 EP1 受体具有高亲和力和选择性的通式（I）化合物。本发明还涉及其制备工艺、用作治疗和/或预防由 EP1 受体介导的疾病或失调的药物以及包含它们的药物组合物。
• Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases
  申请人：Ansorge Siegfried

  公开号：US20070037785A1

  公开（公告）日：2007-02-15

  The present invention relates to substances capable of specifically inhibiting Gly-Pro-p-nitroanilide cleaving peptidases, for a use in the medical field. Furthermore, the invention relates to the use of at least one of such substances or of at least one pharmaceutical or cosmetic composition containing at least one such substance for a prophylaxis or a therapy of diseases, particularly for a prophylaxis and a therapy of diseases accompanied by an excessive immune response (autoimmune diseases, allergies, transplant rejections), of other chronic-inflammatory diseases, of neuronal diseases and cerebral damage, of skin diseases (inter alia acne, psoriasis), of tumor diseases and of specific virus infections (inter alia SARS).
• [DE] NEUE DIPEPTIDYLPEPTIDASE IV-INHIBITOREN ZUR FUNKTIONELLEN BEEINFLUSSUNG UNTERSCHIEDLICHER ZELLEN UND ZUR BEHANDLUNG IMMUNOLOGISCHER, ENTZÜNDLICHER, NEURONALER UND ANDERER ERKRANKUNGEN<br/>[EN] NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS USED FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES<br/>[FR] NOUVEAUX INHIBITEURS DE DIPEPTIDYLPEPTIDASES IV DESTINES A INFLUENCER LE FONCTIONNEMENT DE DIVERSES CELLULES ET A TRAITER DES MALADIES IMMUNOLOGIQUES, INFLAMMATOIRES, NEURONALES ET AUTRES
  申请人：INST MEDIZINTECHNOLOGIE MAGDEB

  公开号：WO2005037779A2

  公开（公告）日：2005-04-28

  Die vorliegende Erfindung betrifft Substanzen, die Gly-Pro-p-Nitroanilid spaltende Peptidasen spezifisch inhibieren, für die Verwendung in der Medizin. Weiter betrifft die Erfindung die Verwendung mindestens einer derartigen Substanz oder mindestens einer mindestens eine derartige Substanz enthaltenden pharmazeutischen oder kosmetischen Zusammensetzung zur Prophylaxe und Therapie von Erkrankungen, insbesondere zur Prophylaxe und Therapie von Erkrankungen mit überschiessender Immunantwort (Autoimmunerkrankungen, Allergien und Transplantatrejektionen), von anderen chronisch-entzündlichen Erkrankungen, neuronalen Erkrankungen und zerebralen Schädigungen, Hauterkrankungen (u. a. Akne und Schuppenflechte), Tumorerkrankungen und speziellen Virusinfektionen (u. a. SARS).